MEDICALHematologyHealth Calculator
🏥

IPI Score

Young patient, localized disease

Understanding IPI ScoreUse the calculator below to check your health metrics

Why This Health Metric Matters

Why: This calculation helps assess important health parameters for clinical and personal wellness tracking.

How: Enter your values above and the calculator will apply validated formulas to compute your results.

  • ●Evidence-based calculations
  • ●Used in clinical settings worldwide
  • ●Regular monitoring recommended
Sources:Medical LiteratureWHO Guidelines

Clinical Scenarios

✅ Very Good Prognosis

Young patient, localized disease

👍 Good Prognosis

Low-intermediate risk

⚠️ Intermediate Risk

High-intermediate risk patient

🔴 High Risk

Poor prognosis patient

👴 Elderly Patient

Geriatric oncology considerations

🧬 Double-Hit Lymphoma

High-risk molecular subtype

🔬 ABC/Non-GCB Type

Activated B-cell subtype

📏 Bulky Disease

Large tumor burden

Patient Information

Disease Staging

⚠️For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.

🏥 Health Facts

— WHO

— CDC

Understanding Diffuse Large B-Cell Lymphoma

DLBCL is the most common type of non-Hodgkin lymphoma, accounting for about 30-40% of all cases. It is an aggressive lymphoma but is potentially curable with immunochemotherapy. The International Prognostic Index (IPI) helps stratify patients into risk groups to guide treatment decisions.

Very Good
94%

4-year OS

IPI: 0-1

Good
79%

4-year OS

IPI: 2

Poor
55%

4-year OS

IPI: 3

Poor
55%

4-year OS

IPI: 4-5

International Prognostic Index (IPI)

Risk FactorAdverse (1 point)Favorable (0 points)
Age>60 years≤60 years
ECOG Performance Status≥20-1
LDH LevelElevated (>ULN)Normal
Ann Arbor StageIII-IVI-II
Extranodal Sites>1 site0-1 sites

Treatment Approach

Standard Treatment: R-CHOP

  • • Rituximab - anti-CD20 antibody
  • • Cyclophosphamide - alkylating agent
  • • Doxorubicin (Hydroxydaunorubicin)
  • • Vincristine (Oncovin)
  • • Prednisone
  • • Typically 6 cycles, every 21 days

High-Risk Options

  • • DA-EPOCH-R - dose-adjusted regimen
  • • CAR-T cell therapy (relapsed/refractory)
  • • Polatuzumab vedotin combinations
  • • Autologous stem cell transplant
  • • Clinical trials

Ann Arbor Staging System

Stage I

Single lymph node region or single extranodal site (IE)

~10% of DLBCL cases

Stage II

≥2 lymph node regions on same side of diaphragm, or localized extranodal (IIE)

~15% of cases

Stage III

Lymph node regions on both sides of diaphragm, ± spleen (IIIS) or extranodal (IIIE)

~25% of cases

Stage IV

Diffuse or disseminated involvement of ≥1 extranodal organs (liver, BM, lung, etc.)

~50% of cases

Modifiers: A = no B symptoms; B = fever, night sweats, weight loss >10%; X = bulky disease (>10 cm or mediastinal mass ratio >1/3); E = extranodal extension

ECOG Performance Status Scale

GradeDescriptionKarnofsky Equivalent
0Fully active, no restrictions100%
1Restricted in strenuous activity, ambulatory and able to do light work80-90%
2Ambulatory, capable of self-care, unable to work, up >50% of waking hours60-70%
3Limited self-care, confined to bed/chair >50% of waking hours40-50%
4Completely disabled, totally confined to bed/chair, no self-care10-30%

Molecular and Genetic Features

Cell of Origin (COO)

GCB (Germinal Center B-cell)

~35-40% of cases. Better prognosis, 75% 5-year OS with R-CHOP.

ABC (Activated B-cell)

~30-35% of cases. Worse prognosis, 45% 5-year OS. May benefit from targeted agents.

Unclassifiable

~10-15% of cases. Intermediate prognosis.

High-Risk Genetic Features

Double-Hit Lymphoma

MYC + BCL2 or BCL6 rearrangements. 5-10% of DLBCL. Very poor prognosis.

Triple-Hit Lymphoma

MYC + BCL2 + BCL6 rearrangements. Extremely poor prognosis.

Double-Expresser

MYC and BCL2 protein overexpression without rearrangement. Intermediate prognosis.

CNS Prophylaxis Considerations

High-Risk Features for CNS Involvement

  • • IPI score 4-5 (CNS-IPI >4)
  • • Double-hit lymphoma
  • • Testicular involvement
  • • Kidney or adrenal involvement
  • • Breast involvement
  • • High LDH (>3× ULN)
  • • Multiple extranodal sites (>2)
  • • Bone marrow involvement

Prophylaxis options: Intrathecal methotrexate (IT MTX) × 4-6 doses, or high-dose IV methotrexate (3-3.5 g/m²) × 2-4 cycles interdigitated with R-CHOP.

Post-Treatment Surveillance

Years 1-2

  • • H&P every 3-6 months
  • • Labs (CBC, LDH) every 3-6 months
  • • CT scan every 6 months × 2 years
  • • PET/CT if concern for recurrence

Years 3-5

  • • H&P every 6-12 months
  • • Labs annually
  • • CT scan annually or as indicated
  • • Cardiac monitoring if anthracycline

Beyond 5 Years

  • • Annual H&P
  • • Labs as indicated
  • • Screen for secondary malignancies
  • • Long-term survivorship care
👈 START HERE
⬅️Jump in and explore the concept!
AI